Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in High-Risk Multiple Myeloma Patients: Interim Analysis of the GMMG-CONCEPT Trial
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
In the first trial with this treatment regimen, quadruplet induction with Isa-KRd in patients with high-risk MM demonstrated promising activity and a tolerable safety profile.
Read More
Anti-CD38 Antibodies in the Treatment of RRMM: Considerations for Pharmacists
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Implementation of a pharmacist on the healthcare team can have significant clinical and economic benefits.
Read More
Subcutaneous Isatuximab Administration by an On-Body Delivery System May Provide a More Convenient Option for Patients with RRMM
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Updated results from a phase 1 trial of subcutaneous isatuximab via OBDS continue to demonstrate an excellent local tolerability with comparable efficacy.
Read More
First Results from a Phase 1 Study of BMS-986393, a GPRC5D-Targeted CAR T-Cell Therapy, in Patients with RRMM
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Preliminary data support the use of BMS-986393 in patients with RRMM despite prior BCMA-directed therapy.
Read More
Subgroup Analysis of CANDOR-Evaluated Outcomes with Carfilzomib plus Dexamethasone and Daratumumab Based on Cytogenetic Risk
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
Data from a subgroup analysis of CANDOR supported the efficacy of daratumumab plus carfilzomib and dexamethasone in RRMM, even in high-risk patients.
Read More
GC012F, an Autologous BCMA and CD19 Dual-Targeting CAR T-Cell Therapy, as First-Line Treatment for Transplant-Eligible Patients with Newly Diagnosed High-Risk Multiple Myeloma
Multiple Myeloma
2022 Year in Review - Multiple Myeloma
A phase 1 trial of GC012F demonstrated an overall response rate of 100% in high-risk, transplant-eligible patients with newly diagnosed multiple myeloma.
Read More
Jaypirca Receives FDA Accelerated Approval for Relapsed or Refractory Mantle-Cell Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
February 2023, Vol 14, No 1
On
January 27, 2023
, the FDA accelerated the approval of pirtobrutinib (Jaypirca; Eli Lilly) for the treatment of patients with relapsed or refractory mantle-cell lymphoma (MCL) after at least 2 lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor.
Read More
FDA Grants Lunsumio Accelerated Approval for Relapsed or Refractory Follicular Lymphoma
FDA Approvals, News & Updates
,
Lymphoma
February 2023, Vol 14, No 1
On
December 22, 2022
, the FDA accelerated the approval of mosunetuzumab-axgb (Lunsumio; Genentech), a bispecific CD20-directed CD3 T-cell engager, for adults with relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy. The FDA granted this indication breakthrough therapy and orphan drug designations.
Read More
Results from Phase 3 Trial Show Similar Efficacy and Safety Outcomes with CT-P16 versus Bevacizumab in Patients with NSCLC
Biosimilars
Web Exclusives
One-year follow-up data from a phase 3 study found similar duration of response, time to progression (TTP), and survival rates with the biosimilar candidate CT-P16 compared with its reference drug, bevacizumab (Avastin), in the first-line treatment of patients with metastatic or recurrent nonsquamous non–small-cell lung cancer (NSCLC).
Read More
Biosimilar Substitution May Reduce Financial Risk to Providers in Value-Based Payment Models
By
Wayne Kuznar
Biosimilars
,
ASCO 2022 Highlights
February 2023, Vol 14, No 1
Providers participating in the Centers for Medicare & Medicaid Services’ (CMS’) value-based payment (VBP) models may realize a reduction in financial risk via biosimilar substitution.
Read More
Page 13 of 339
10
11
12
13
14
15
16
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Addressing Cancer Health Disparities: The No One Left Alone Initiative
Rohan Nathwani
,
Arva Patel
,
Warner Kornberg
,
Asutosh Gor, MD
,
Sashi Naidu, MD
,
Viral Rabara, MD
,
Niyati Nathwani, MD
,
Kashyap Patel, MD
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma